A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease.
Maslak, P G 1,4; Dao, T 2,4; Gomez, M 2; Chanel, S 1; Packin, J 2; Korontsvit, T 2; Zakhaleva, V 2; Pinilla-lbarz, J 3; Berman, E 1; Scheinberg, D A 1,2
[Letter]
Leukemia.
22(8):1613-1616, August 2008.
(Format: HTML, PDF)